9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease

Clinical trial NCT01086553 · COMPLETED

Trial details

NCT number: NCT01086553
Sponsor: Dr. Falk Pharma GmbH
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Crohn´s Disease

Start date: 2009-11-01
Primary completion: 2012-05-01
Enrollment: 471

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.